Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact

Preliminary Evaluation of 99mTc-Labeled Peptide p5+14 (AT-05) for the Detection of Cardiopulmonary Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging

May 28, 2024 Posters & Publications

Click Here to View...

Relationship Between Myocardial 124I-evuzamitide Uptake and Extracellular Volume Fraction: A Cardiac PET/MRI Study

May 28, 2024 Posters & Publications

Click Here to View...

First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis

May 28, 2024 Posters & Publications

Click Here to View...

Changes in Organ-Specific Amyloid Load Assessed by Serial PET/CT Imaging of Iodine (124I) Evuzamitide – Correlation with Serum Biomarkers

May 28, 2024 Posters & Publications

Click Here to View...

Temporal Changes in the Renal Cytokine Profile in Response to AA Amyloidosis Induce Macrophage Infiltration Enabling Host-Mediated Targeting of Therapeutic Chimeric Antigen Receptor Macrophages (CARM)

May 27, 2024 Posters & Publications

Click Here to View...
« Older Entries
Next Entries »

Recent Posts

  • Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
  • Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
  • Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
  • Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
  • Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors

SCIENCE
Approach
PAR Therapeutics

PIPELINE

NEWS
Press Releases
Posters & Publications

AMYLOIDOSIS
CAREERS
CONTACT

  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow
Attralus logo

Attralus, Inc.
365 Fifth Ave South, Ste 208
Naples, FL 34102

©2026 Attralus, Inc.  All Rights Reserved.